Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro : implications for prediction of metabolic interactions in vivo

References

• BAGULEY, B. C., ZHUANG, L. and KESTELL, P., 1997, Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncology Research, 9, 55–60.
   PubMed Web of Science ®Google Scholar
• BALANT, L. P. and GEX-FABRY, M., 1990, Physiological pharmacokinetic modelling. Xenobiotica, 20, 1241–1257.
   Google Scholar
• BOGAARDS, J. J. P., BERTRAND, M., JACKSON, P., OUDSHOORN, M. J., WEAVER, R. J., VAN BLANDEREN, P. J. and WALTHER, B., 2000, Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica, 30, 1131–1152.
   Google Scholar
• BOOBIS, A. R., SESARDIC, D., MURRAY, B. P., EDWARDS, R. J., SINGLETON, A. M., RICH, K. J., MURRAY, S., DE LA TORRE, R., SEGUFtA, J., PELKONEN, 0., PASANEN, M., KOBAYASHI, S., ZHI-GUANG, T. and DAVIES, D. S., 1990, Species variation in the response of the cytochrome P450-dependent monooxygenase system to inducers and inhibitors. Xenobiotica, 20, 1139–1161.
   Google Scholar
• BOXENBAUM, H., 1980, Interspecies variation in liver weight, hepatic weight, hepatic flow and antipyrine intrinsic clearance in extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokinetics and Biophamaceutics, 8, 165–176.
   PubMedGoogle Scholar
• BOXENBAUM, H., 1982, Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics, 10, 201–227.
   PubMedGoogle Scholar
• BRUNELLE, F. M. and VERBEECK, R. K., 1996, Glucuronidation of diflunisal in liver and kidney microsomes of rat and man. Xenobiotica, 26, 123–131.
   PubMed Web of Science ®Google Scholar
• BURCHELL, B., BRIELEY, C. H., MONAGHAN, G. and CLARKE, D. J., 1998, The structure and function of the UDP-glucuronosyltransferase gene family. Advances in Pharmacology, 42, 335–338.
   PubMedGoogle Scholar
• CARLILE, D. J., HAKOOZ, N., BAYLISS, M. K. and HOUSTON, J. B., 1999, Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. British Journal of Clinical Pharmacology, 47, 625–635.
   PubMed Web of Science ®Google Scholar
• CHING, L.-M., Xu, Z.-F., GUMMER, B. H., PALMER, B. D., JOSEPH, W. R. and BAGULEY, B. C., 1995, Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dirnethylxanthenone-4-acetic acid. British Journal of Cancer, 72, 339–343.
   PubMed Web of Science ®Google Scholar
• CUMMINGS, J., DOUBLE, J. A., BIBBY, M. C., FARMER, P., EVENS, S., KERR, D. J., KAYE, S. B. and SMYTH, J. F., 1989, Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice. Cancer Research, 49, 3587–3593.
   PubMed Web of Science ®Google Scholar
• DAVIDSON, I. W. F., PARKER, J. C. and BELILES, R. P., 1986, Biological basis for extrapolation across mammalian species. Regulatory Toxicology and Pharmacology, 6, 211–237.
   Google Scholar
• DE MONTELLANO, P. R. 0., 1999, The cytochrome P450 oxidative system. In T. F. Woolf (ed.), Handbook of Drug Metabolism (New York: Marcel Dekker), pp. 203–227.
   Google Scholar
• DIXON, P. A., CALDWELL, J. and SMITH, R. L., 1977, Metabolism of arylacetic acids. 1. The fate of 1-naphthylacetic acid and its variation with species and dose. Xenobiotica, 7, 695–706.
   PubMed Web of Science ®Google Scholar
• EAGLING, V. A., TPA, J. F. and BACK, D. J., 1998, Differential selectivity of cytochrome P450 inhibitors against probes substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45, 107–114.
   PubMed Web of Science ®Google Scholar
• EMUDIANUGHE, T. S., CALDWELL, J. and SMITH, R. L., 1987, Studies on the metabolism of arylacetic acids. 6. Comparative metabolic conjugation of 1- and 2-naphthylacetic acids in the guinea pig, mouse, hamster and gerbil. Xenobiotica, 17, 815–821.
   PubMed Web of Science ®Google Scholar
• GIBALDI, M. and PERRIER, D., 1982, Pharmacokinetics (New York: Marcel Dekker).
   Google Scholar
• GORROD, J. W. and DAMANI, L. A., 1979, The effect of various potential inhibitors, activators and inducers on the N-oxidation of 3-substituted pyridines in vitro. Xenobiotica, 9, 219–226.
   PubMed Web of Science ®Google Scholar
• GRAM, T. E., OKINE, L. K. and GRAM, R. A., 1986, The metabolism of xenobiotics by certain extrahepatic organs and its relation to toxicity. Annual Review in Pharmacology and Toxicology, 26, 259–292.
   PubMed Web of Science ®Google Scholar
• GUYTON, A. C., 1981, Textbook of medical Physiology (London: W. B. Saunders).
   Google Scholar
• HALPERT, J. R., GUENGERICH, F. P., BEND, J. R. and CORREIA, M. A., 1994, Selective inhibitors of cytochromes P450. Toxicology and Applied Pharmacology, 125, 163–175.
   PubMed Web of Science ®Google Scholar
• HOUSTON, J. B., 1994, Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemical Pharmacology, 47, 1469–1479.
   PubMed Web of Science ®Google Scholar
• Do, K., IWATSUBO, T., KANAMITSU, S., NUKAJIMA, Y. and SUGIYAMA, Y., 1998, Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annual Review of Pharmacology and Toxicology, 38, 461–499.
   PubMed Web of Science ®Google Scholar
• JAMESON, M. B., THOMSON, P. I., BAGULEY, B. C., EVANS, B. D., HARVEY, V. J., MCCRYSTAL, M. R. and KESTELL, P., 2000. Phase I pharmacokinetic and pharmacodynamic study of 5,6-dirnethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. In Proceeding of the Annual Meeting of American Society of Clinical Oncologists, pp. 705.
   Google Scholar
• KESTELL, P., PAXTON, J. W., REWCASTLE, G. W., DUNLOP, I. and BAGULEY, B. C., 1999, Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dirnethylxanthenone-4-acetic acid in the mouse, rat and rabbit. Cancer Chemotherapy and Pharmacology, 43, 323–330.
   PubMed Web of Science ®Google Scholar
• KESTELL, P., ZHAO, L., CUING, L.-M., BAGULEY, B. C. and PAXTON, J. W., 2000, Modulation of the plasma pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid by thalidomide in mice. Cancer Chemotherapy and Pharmacology, 46, 135–141.
   Google Scholar
• KRISHNA, D. R. and KLUTZ, U., 1994, Extrahepatic metabolism of drugs in humans. Clinical Pharmacokinetics, 26, 144–160.
   PubMed Web of Science ®Google Scholar
• LASH, C. J., Li, A. E., RUTLAND, M., BAGULEY, B. C., Zwi, L. J. and WILSON, W. R., 1998, Enhancement of the anti-tumour effects of the antivascular agent 5,6-dirnethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. British Journal of Cancer, 78, 439–445.
   PubMed Web of Science ®Google Scholar
• LEWIS, D. F., IONNIDES, C. and PARKE, D. V., 1998, Cytochrome P450 and species differences in xenobiotic metabolism and activation of carcinogen. Environmental and Health Perspectives, 106, 633–641.
   PubMed Web of Science ®Google Scholar
• LIN, J. H., 1998, Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metabolism and Disposition, 26, 1202–1212.
   PubMed Web of Science ®Google Scholar
• LOHR, J. W., WILLSKY, G. R. and ACARA, M. A., 1998, Renal drug metabolism. Pharmacological Review, 50, 107–141.
   PubMed Web of Science ®Google Scholar
• MAHMOOD, I., 1999, Allometric issues in drug development. Journal of Pharmaceutical Science, 88, 1101–1106.
   PubMed Web of Science ®Google Scholar
• MINERS, J. 0., VALENTE, L., LILLYWHITE, K. J., MACKENZIE, P. I., BURCHELL, B., BAGULEY, B. C. and KESTELL, P., 1997, Preclinical prediction of factors influencing the elimination of 5,6 – dirnethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Research, 57, 284–289.
   Google Scholar
• MODENTI, J., 1986, Dosage regimen design for pharmaceutical studies conducted in animals. Journal of Pharmaceutical Science, 75, 852–856.
   PubMed Web of Science ®Google Scholar
• MOODY, G. C., GRIFFIN, S. J., MATHER, A. N., MCGINNITY, D. F. and RILEY, R. J., 1999, Fully automated analysis of activities catalysed by the major human liver cytochrome P450(CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica, 29, 53–75.
   PubMed Web of Science ®Google Scholar
• NEDELCHEVA, D. and GUT, I., 1994, P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica, 24, 1151–1175.
   PubMed Web of Science ®Google Scholar
• OBACH, R. S., 1997, Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, irnipramine, and propranolol. Drug Metabolism and Disposition, 25, 1359–1369.
   PubMed Web of Science ®Google Scholar
• OBACH, R. S., 1999, Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metabolism and Disposition, 27, 1350–1359.
   PubMed Web of Science ®Google Scholar
• OMURA, T. and SATO, R., 1964, The carbon monoxide binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 23, 2370–2378.
   Google Scholar
• PAXTON, J. W., 1995, The allometric approach for interspecies scaling of pharmacokinetics and toxicity of anticancer drugs. Clinical and Experimental Pharmacology and Physiology, 22, 851–854.
   PubMed Web of Science ®Google Scholar
• PHILPOTT, M., BAGULEY, B. C. and CHING, L.-M., 1995, Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dirnethylxanthenone-4-acetic acid. Cancer Chemotherapy and Pharmacology, 36, 143–148.
   Google Scholar
• PRUIJN, F. B., VANDAALEN, M., HOLFORD, N. H. G. and WILSON, W. R., 1997, Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemotherapy and Pharmacology, 39, 541–546.
   Google Scholar
• RADOMINSKA-PANDYA, A., CZERNIK, P. J., LITTLE, J. M., BATTAGLIA, E. and MACKENZIE, P. I., 1999, Structural and functional studies of UDP-glucuronosyltransferases. Drug Metabolism Reviews, 31, 817–899.
   Google Scholar
• REWCASTLE, G. W., ATWELL, G. J., BAGULEY, B. C., CALVELEY, S. B. and DENNY, W. A., 1989, Potential antitumour agents. 58. Synthesis and structure—activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumour in vivo. Journal of Medicinal Chemistry, 32, 793–799.
   PubMed Web of Science ®Google Scholar
• REWCASTLE, G. W., KESTELL, P., BAGULEY, B. C. and DENNY, W. A., 1990, Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution. Journal of the National Cancer Institute, 82, 528–529.
   PubMedGoogle Scholar
• ROBERTS, M. S. and ROWLAND, M., 1986, A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. Journal of Pharmacokinetks and Biopharmaceutics, 14, 227–260.
   PubMedGoogle Scholar
• ROBSON, R. A., MATTHEWS, A. P., MINERS, J. 0., McMANus, M. E., MEYER, U. A., HALL, P. D. and BIRKETT, D. J., 1987, Characterisation of theophylline metabolism by human liver microsomes. British Journal of Clinical Pharmacology, 24, 293–300.
   Google Scholar
• ROWLAND, M., BENET, L. Z. and GRAHAM, G. G., 1973, Clearance concepts in pharmacokinetics. Journal of Pharmacokinetks and Biopharmaceutics, 1, 123–136.
   PubMedGoogle Scholar
• SALLUSTIO, B. C., PURDIE, Y. J., BIRKETT, D. J. and MEFFIN, P. J., 1989, Effect of renal dysfunction on the individual components of the acyl-glucuronide futile cycle. Journal of Pharmacology and Experimental Therapeutics, 251, 288–294.
   PubMed Web of Science ®Google Scholar
• SCHILLINGS, R. T. and SISENWINE, S. F., 1986, Disposition of (5H-dibenzo [a,d]cyclohepten-5-ylidene)acetic acid in laboratory animals. Drug Metabolism and Disposition, 14, 405–412.
   PubMed Web of Science ®Google Scholar
• SESARDIC, D., BOOBIS, A. R., MURRAY, B. P., MURRAY, S., SEGURA, J., DE LA TORRE, R. and DAVIES, D. S., 1990, Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. British Journal of Clinical Pharmacology, 29, 651–663.
   PubMed Web of Science ®Google Scholar
• SMITH, P. K., KROHN, R. I., HERMANSON, G. T., MALLIA, A. K., GARTER, F. H., PROVENZANO, M. D., FUJIMOTO, E. K., GOEKE, N. M., OLSON, B. J. and KLENK, D. C., 1985, Measurement of protein using bicinchoninic acid. Analytical Biochemistry, 150, 76–85.
   PubMed Web of Science ®Google Scholar
• THOMSEN, L. L., CHING, L.-M. and BAGULEY, B. C., 1990, Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid. Cancer Research, 50, 6966–6970.
   Google Scholar
• THOMSEN, L. L., CHING, L.-M., ZHUANG, L., GAVIN, J. B. and BAGULEY, B. C., 1991, Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Research, 51, 77–81.
   Google Scholar
• UBEAUD, G., SCHMITT, C., JAECK, D., LAVE, T. and COASSOLO, P. H. H., 1995, Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data. Xenobiotica, 25, 1381–1390.
   PubMed Web of Science ®Google Scholar
• VERONESE, M. E., McMANus, M. E., LAUPATTARAKASEM, P., MINERS, J. 0. and BIRKETT, D. J., 1990, Tolbutarnide hydroxylation by human, rabbit and rat liver microsomes and by purified forms of cytochrome P-450. Drug Metabolism and Disposition, 18, 356–361.
   Google Scholar
• WEBSTER, L. K., Ews, A. G., KESTELL, P. and REWCASTLE, G. W., 1995, Metabolism and elimination of 5,6-dirnethylxanthenone-4-acetic acid in the isolated perfused rat liver. Drug Metabolism and Disposition, 23, 363–368.
   PubMed Web of Science ®Google Scholar
• WILKINSON, G. R., 1975, A physiological approach to hepatic drug clearance. Clinical Pharmacology and Therapeutics, 18, 377–390.
   PubMed Web of Science ®Google Scholar
• WILSON, W. R., Li, A. E., COWAN, D. S. M. and Sim, B. G., 1998, Enhancement of tumor radiation response by the antivascular agent 5,6-dirnethylxanthenone-4-acetic acid. International Journal of Radiation Oncology Biology Physics, 42, 905–908.
   Google Scholar
• WOODHOUSE, K., 1992, Drugs and the liver. Part III: Ageing of the liver and the metabolism of drugs. Biopharmaceutics and Drug Disposition, 13, 311–320.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION, 1979, WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48 (Geneva: WHO).
   Google Scholar
• ZAHARKO, D. S., GRIESHABER, C. K., PLOWMAN, J. and CRADOCK, J. C., 1986, Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumors. Cancer Treatment Reports, 70, 1415–1421.
   PubMedGoogle Scholar
• ZHAO, L., KETSELL, P., ZHUANG, L. and BAGULEY, B. C., 2001, Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetic of 5,6-dimethylxanthenone-4-acetic (DMXAA). Cancer Chemotherapy and Pharmacology, 47, 491–497.
   PubMed Web of Science ®Google Scholar
• ZHou, S. F., PAXTON, J. W., TINGLE, M. D., McCALL, J. and KESTELL, P., 1999, Determination of two major metabolites of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography ( B), 734, 129–136.
   PubMed Web of Science ®Google Scholar
• ZHou, S. F., PAXTON, J. W., TINGLE, M. D. and KESTELL, P., 2000, Identification of the human liver cytochrome P450 isozyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metabolism and Disposition, 28, 1449–1456.
   PubMed Web of Science ®Google Scholar
• ZHou, S. F., PAXTON, J. W., TINGLE, M. D., KESTELL, P. and CHING, L.M., 2001a, In vitro and in vivo kinetic interactions of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac. Cancer Chemotherapy and Pharmacology, 47, 319–326.
   PubMed Web of Science ®Google Scholar
• ZHou, S. F., KESTELL, P., TINGLE, M. D., CHING, L.-M. and PAXTON, J. W., 2001b, A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dirnethylxanthenone-4-acetic acid with thalidomide. Cancer Chemotherapy and Pharmacology, 47, 541–544.
   Google Scholar
• ZHou, S. F., PAXTON, J. W., KESTELL, P. and TINGLE, M. D., 2001c, Reversible binding of the novel anti-tumour agent 5,6-dirnethylxanthenone-4-acetic acid to plasma proteins and blood cells in various species. Journal of Pharmacy and Pharmacology, 53, 463–471.
   PubMed Web of Science ®Google Scholar
• Zwi, L. J., BAGULEY, B. C., GAVIN, J. B. and WILSON, W. R., 1989, Blood flow failure as a major determinant in the antitumor action of flavone acetic acid (NSC 347512). Journal of the National Cancer Institute, 81, 1005-1 013.
   PubMedGoogle Scholar
• Zwi, L. J., BAGULEY, B. C., GAVIN, J. B. and WILSON, W. R., 1994, Correlation between immune and vascular activities of xanthenone acetic acid on tumour agents. Oncology Research, 6, 79–85.
   PubMed Web of Science ®Google Scholar